“…For example, nafamostat mesylate, inhibits coronavirus entrance into human epithelial cells (EC 50 10 mM), as well as hypercoagulopathy [[ 50 ]]. There are also drugs that were shown to improve COVID-19 clinical symptoms, like convalescent plasma, corticosteroids, favipiravir, ribavirin, galidesivir, sofosbuvir, hydroxychloroquine (HCQ), azithromycin, doxycycline, lopinavir, heparin, tissue plasminogen activator, stilbene, ebelsen, metformin, tocilizumab, aculizumab, interferon β and γ, interleukinin 1 inhibitors, mesenchymal stem cells, nitric oxide, cannabidiol, N-acetylcysteine, calcifediol, vitamin C and D [[ 14 , [51] , [52] , [53] , [54] , [55] , [56] , [57] , [58] , [59] , [60] ]]. Up to now, the most promising one is remdesivir, which is approved for emergency use by FDA [ www.fda.gov/drugs/drug-safety-and-availability/fdas-approval-veklury-remdesivir-treatment-covid-19-science-safety-and-effectiveness ], but the clinical trials are ongoing [[ 60 , 61 ]].…”